The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes

International Journal of Geriatric Psychiatry

Volumn 22, Issue 9, 2007, Pages 843-849

  Selbæk, Geir ^a,b   Kirkevold, Øyvind ^c,d   Engedal, Knut ^a,b,e  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c Vestfold Mental Health Care Trust   (Norway)

^d UNIVERSITY OF AGDER   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Behavioural; Dementia; Nursing homes; Psychiatric

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT;

AGED; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; DRUG USE; FEMALE; HUMAN; LAWTON INSTRUMENTAL ACTIVITIES OF DAILY LIVING SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MENTAL DISEASE; NORWAY; NURSING HOME; NURSING HOME PATIENT; PRESCRIPTION; PREVALENCE; RATING SCALE; SAMPLE SIZE;

AGED; BEHAVIORAL SYMPTOMS; DEMENTIA; DISEASE PROGRESSION; HOMES FOR THE AGED; HUMANS; NORWAY; NURSING HOMES; PREVALENCE; PSYCHOTROPIC DRUGS;

EID: 34648831622     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.1749     Document Type: Article

References (26)

1. Aalten P, de Vugt ME, Jaspers N, et al. 2005. The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study. Int J Geriatr Psychiatry 20(6): 523-530.
2. Ballard C, Howard R. 2006. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7(6): 492-500.
3. Ballard C, Margallo-Lana M, Juszczak E, et al. 2005. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ 330(7496): 874.
4. Brodaty H, Draper B, Saab D, et al. 2001. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 16(5): 504-512.
5. Burns A, Jacoby R, Levy R. 1990. Psychiatric phenomena in Alzheimer's disease. III: Disorders of mood. Br J Psychiatry 157: 81-84.
6. Cummings JL, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44(12): 2308-2314.
7. Gobert M, D'hoore W. 2005. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland. Int J Geriatr Psychiatry 20(8): 712-721.
8. Holmes C, Wilkinson D, Dean C, et al. 2004. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 63(2): 214-219.
9. Hosia-Randell H, Pitkala K. 2005. Use of psychotropic drugs in elderly nursing home residents with and without dementia in Helsinki, Finland. Drugs Aging 22(9): 793-800.
10. Hughes CP, Berg L, Danziger WL, et al. 1982. A new clinical scale for the staging of dementia. Br J Psychiatry 140: 566-572.
11. Kirkevold O, Engedal K. 2005. Concealment of drugs in food and beverages in nursing homes: cross sectional study. BMJ 330(7481): 20.
12. Lawton MP, Brady EM. 1969. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9(3): 179-186.
13. Lovheim H, Sandman PO, Kallin K, et al. 2006. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 18(4): 713-726.
14. Lyketsos CG, Steinberg M, Tschanz JT, et al. 2000. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 157(5): 708-714.
15. Margallo-Lana M, Swann A, O'Brien J, et al. 2001. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 16(1): 39-44.
16. Nygaard HA, Ruths S. 2003. Missing the diagnosis: senile dementia in patients admitted to nursing homes. Scand J Prim Health Care 21(3): 148-152.
17. Nygaard HA, Ruths S, Straand J, Naik M. 2004. Not less but different: psychotropic drug utilization trends in Norwegian nursing homes during a 12-year period. The Bergen District Nursing Home (BEDNURS) Study. Aging Clin Exp Res 16(4): 277-282.
18. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. 2004. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr 16(1): 61-74.
19. Reifler BV, Teri L, Raskind M, et al. 1989. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 146(1): 45-49.
20. Ropacki SA, Jeste DV. 2005. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 162(11): 2022-2030.
21. Schneider LS, Dagerman KS, Insel P. 2006. Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials. Am J Geriatr Psychiatry 14(3): 191-210.
22. Snowdon J, Day S, Baker W. 2006. Current use of psychotropic medication in nursing homes. Int Psychogeriatr 18(2): 241-250. DOI: 10.1017/S1041610205002449
23. Sourial R, McCusker J, Cole M, Abrahamowicz M. 2001. Agitation in demented patients in an acute care hospital: prevalence, disruptiveness, and staff burden. Int Psychogeriatr 13(2): 183-197.
24. Statistics Norway. 2005. Municipal Health and Care Statistics, Oslo.
25. Steinberg M, Sheppard JM, Tschanz JT, et al. 2003. The incidence of mental and behavioral disturbances in dementia: the cache county study. J Neuropsychiatry Clin Neurosci 15(3): 340-45.
26. Waite L, Grayson D, Jorm AF, et al. 1999. Informant-based staging of dementia using the clinical dementia rating. Alzheimer Dis Assoc Disord 13(1): 34-37.